Clinical Trial Update: Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating polypodium leucotomos extract showed efficacy in reducing UVA-induced premutagenic and photoaging markers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging
• Skin Abnormalities

Drugs mentioned

• Polypodium leucotomos extract (Polypodium leucotomos extract)

Snippet

Sponsor: University of Miami | Conditions: Aging, Skin Abnormalities | Phase 2 | Status: COMPLETED | Results posted: 2019-06-18